1. Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step
   Ralf Weiskirchen, 2016, Front. Pharmacol. CrossRef
2. The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease
   María Teresa Arias-Loste et al, 2015, BioMed Research International CrossRef
3. Gut Microbiota and Host Reaction in Liver Diseases
   Hiroshi Fukui, 2015, Microorganisms CrossRef
4. The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels
   Ralf Weiskirchen et al, 2015, Front. Physiol. CrossRef
5. Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma
   Naz Fatima et al, 2017, Canadian Journal of Gastroenterology and Hepatology CrossRef
6. Molecular Pathogenesis of NASH
   Alessandra Caligiuri et al, 2016, IJMS CrossRef
7. Screening of differentially expressed protein kinases in bone marrow endothelial cells and the protective effects of the p38a inhibitor SB203580 on bone marrow in liver fibrosis
   Bo Gao et al, 2016 CrossRef
8. Short-Term Intake of a Fructose-, Fat- and Cholesterol-Rich Diet Causes Hepatic Steatosis in Mice: Effect of Antibiotic Treatment
   Annette Brandt et al, 2017, Nutrients CrossRef
9. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
   Tadashi Namisaki et al, 2017, Hepatology Communications CrossRef
10. DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis
    Kiyoshi Asada et al, 2016, WJH CrossRef
11. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease.
    Marco Poeta et al, 2017, Children (Basel) CrossRef
12. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
    Kosuke Kaji et al, 2017, WJG CrossRef
13. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota
    Sena Bluemel et al, 2016, American Journal of Physiology-Gastrointestinal and Liver Physiology CrossRef
14. Effect of the acute heat stress on serum endotoxin concentration and the expression of TLR4 mRNA in liver of Arbor Acres broiler chickens
    Shu-cheng Huang et al, 2018, Anim. Prod. Sci. CrossRef
15. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis
    Waleska Dornas et al, 2019, Pharmacological Research CrossRef
16. Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis
    Noha F. Hassan et al, 2019, Inflammation CrossRef
17. Intestinal Trefoil Factor 3 Alleviating the Intestinal Barrier Function Through Reducing the Expression of TLR4 in Rats With Nonalcoholic Steatohepatitis
    Yingchun Wang et al, 2019, Archives of Medical Research CrossRef
18. Sodium butyrate protects mice from the development of the early signs of non-alcoholic fatty liver disease: role of melatonin and lipid peroxidation
    Cheng Jun Jin et al, 2016, Br J Nutr CrossRef
19. Cytochrome P450-2E1 promotes fast food-mediated hepatic fibrosis
    Mohamed A. Abdelmegeed et al, 2017, Sci Rep CrossRef
20. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention
    Marialena Mouzaki et al, 2019, Therap Adv Gastroenterol CrossRef
21. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis
    Naotaka Shimozato et al, 2019, Hepatol Res CrossRef
22. The Gut Microbiota and Liver Disease
    Cristina Llorente et al, 2015, Cellular and Molecular Gastroenterology and Hepatology CrossRef
23. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
    Tadashi Namisaki et al, 2016, J Gastroenterol CrossRef
24. A Bugs Battle on Behalf of the Liver
    Mariana Verdelho Machado, 2016, GE Portuguese Journal of Gastroenterology CrossRef
25. Palmitic acid elicits hepatic stellate cell activation through inflammasomes and hedgehog signaling
    Na-Na Duan et al, 2017, Life Sciences CrossRef
26. Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids
    Aafke W. F. Janssen et al, 2017, J. Lipid Res. CrossRef
27. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression
    Dishen Chen et al, 2019, Cells CrossRef
28. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
    Hiroshi Fukui, 2019, Diseases CrossRef
29. Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways
    Jafar Ai et al, 2019, Cancer Cell Int CrossRef
30. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
    Takahiro Ozutsumi et al, 2020, IJMS CrossRef
31. Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients.
    Kosuke Kaji et al, 2020, Antibiotics (Basel) CrossRef
32. Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model
    Kenichiro Seki et al, 2018, Oncotarget CrossRef
33. Lipopolysaccharides transport during fat absorption in rodent small intestine
    Yasutada Akiba et al, 2020, American Journal of Physiology-Gastrointestinal and Liver Physiology CrossRef
34. Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
    Yuki Tsuji et al, 2020, Microorganisms CrossRef
35. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
    Yukihisa Fujinaga et al, 2020, Int J Mol Sci CrossRef
36. Targeting the gut-liver-immune axis to treat cirrhosis
    Thomas Henry Tranah et al, 2020, Gut CrossRef
37. Hyperbaric Oxygen Treatment Improves Intestinal Barrier Function After Spinal Cord Injury in Rats
    Xuehua Liu et al, 2020, Front. Neurol. CrossRef
38. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage
    Julio Plaza-Díaz et al, 2020, IJMS CrossRef
39. Effects of Gut Metabolites and Microbiota in Healthy and Marginal Livers Submitted to Surgery
    Marc Micó-Carnero et al, 2020, IJMS CrossRef
40. Gut microbiota and systemic immunity in health and disease
    Bernard C Lo et al, 2020 CrossRef
41. Gut–Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers
    Antonio Gil-Gómez et al, 2021, Semin Liver Dis CrossRef
42. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity
    Patricia Lamadrid et al, 2021, Front. Immunol. CrossRef
43. Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis
    Norihisa Nishimura et al, 2021, IJMS CrossRef
44. Chronic hepatitis С and non-alcoholic fatty liver disease. Main aspects of pathogenesis
    K V Zhdanov et al, 2018, Bulletin of the Russian Military Medical Academy CrossRef
45. Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function
    Josh Bilson et al, 2021, Proc. Nutr. Soc. CrossRef
46. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
    Xiao Yu et al, 2022, Front. Cell. Infect. Microbiol. CrossRef
47. Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems
    Jacqueline Córdova-Gallardo et al, 2021 CrossRef
48. Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function
    Kunihiko Yokoyama et al, 2022, PLoS ONE CrossRef
49. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis
    Tadashi Namisaki et al, 2022, Indian J Gastroenterol CrossRef
50. Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma
    Sj Shen et al, 2022, Cancers CrossRef
51. Gut Microbiota and Hepatocellular Carcinoma
    Xuemei Tao et al, 2015, Gastrointest Tumors CrossRef
52. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?
    Hiroshi Fukui, 2016, Inflamm Intest Dis CrossRef
53. Changes of Intestinal Functions in Liver Cirrhosis
    Hiroshi Fukui et al, 2016, Inflamm Intest Dis CrossRef
54. Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD.
    Guido Carpino et al, 2020, Hepatology CrossRef
55. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective
    Lijun Luo et al, 2023, Life Sciences CrossRef
56. Protective role of cGAS in NASH is related to the maintenance of intestinal homeostasis
    Marcelle de Carvalho Ribeiro et al, 2023, Liver International CrossRef
57. Increasing the prepartum dose of rumen-protected choline: Effects of maternal choline supplementation on growth, feed efficiency, and metabolism in Holstein and Holstein × Angus calves
    H.T. Holdorf et al, 2023, Journal of Dairy Science CrossRef
58. Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis
    Roman Maslennikov et al, 2023, IJMS CrossRef
59. Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
    Changrui Long et al, 2024, Biology CrossRef
60. Immune landscape of hepatocellular carcinoma: From dysregulation of the immune responses to the potential immunotherapies
    Atieh Pourbagheri‐Sigaroodi et al, 2024, Cell Biochemistry & Function CrossRef
61. Changes in intestinal permeability and gut microbiota following diet-induced weight loss in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis
    Dimitrios A. Koutoukidis et al, 2024, Gut Microbes CrossRef
62. Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Salim Maher et al, 2024, Semin Liver Dis CrossRef